GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: This is an orally bioactive small molecule inhibitor of IL-17A interaction with its receptor and IL-17-mediated inflammation [1]. It is one of the compounds that are claimed in Dice Therapeutics' development pipeline. There are two named leads in their pipeline (DC-806 and DC-853 [2]) and a third unnamed lead, but as of May 2025 no name to structure(s) have been formally disclosed for these. DC-806 and DC-853 are both in phase 2 studies for plaque psoriasis.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
Database Links ![]() |
|
| GtoPdb PubChem SID | 513757596 |
| PubChem CID | 156188935 |
| Search Google for chemical match using the InChIKey | JQJIKYJEWUSKJS-GVIAMBBFSA-N |
| Search Google for chemicals with the same backbone | JQJIKYJEWUSKJS |
| UniChem Compound Search for chemical match using the InChIKey | JQJIKYJEWUSKJS-GVIAMBBFSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | JQJIKYJEWUSKJS-GVIAMBBFSA-N |